Palatin Technologies stock (US69608A1088): Q3 revenue jumps to $3.9M, loss narrows

Palatin Technologies reported Q3 fiscal 2026 results on May 13 with $3.9M collaboration revenue versus zero last year, net loss of $1.43M and cash at $10.2M.

Palatin Technologies released its third quarter fiscal 2026 results on May 13, 2026, for the period ended March 31, 2026, marking a shift to collaboration-driven revenue. The company posted $3.9 million in quarterly collaboration and license revenue, up from nothing in the prior-year period, primarily from a Boehringer Ingelheim agreement and a $3.75 million non-cash license to Altanispac Labs, Stock Titan as of 05/13/2026. Nine-month revenue reached $12.9 million. Net loss narrowed to $1.43 million from prior periods, with cash and equivalents at $10.2 million.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Palatin Technologies, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Peptide therapeutics
• Key revenue drivers: Licensing and collaborations
• Home exchange/listing venue: NYSE American (PTN)
• Trading currency: USD

Palatin Technologies: core business model

Palatin Technologies develops peptide-based therapeutics targeting unmet medical needs in areas like dry eye disease, retinal disease, and cancer. The company focuses on melanocortin receptor agonists and other proprietary platforms, transitioning from pure R&D to revenue-generating partnerships, as shown in its Q3 fiscal 2026 10-Q filing published May 13, 2026, Stock Titan as of 05/13/2026.

Key programs include PL9643 for dry eye, in partnership discussions, and retinal disease candidates licensed to Boehringer Ingelheim. Recent financings, including a November 2025 public offering raising $18.2 million gross proceeds, bolstered its balance sheet to $10.6 million in stockholders' equity as of March 31, 2026.

Main revenue and product drivers for Palatin Technologies

Collaboration and license revenue drove Q3 fiscal 2026 results, with $3.9 million in the quarter and $12.9 million over nine months ended March 31, 2026, versus zero prior year, per the SEC 10-Q summarized on Stock Titan as of 05/13/2026. This includes a non-cash $3.75 million PL9643 sublicense to Altanispac Labs and Boehringer Ingelheim payments.

EPS of $(0.37) beat consensus estimates of $(1.26), with R&D expenses at $3.5 million and G&A at $2.0 million for the quarter, Sahm Capital as of 05/13/2026. Cash position of $10.2 million supports ongoing clinical development, relevant for US biotech investors tracking small-cap revenue inflection points.

Why Palatin Technologies matters for US investors

Listed on NYSE American, Palatin Technologies offers US investors exposure to peptide therapeutics innovation amid a robust domestic biotech sector. Its recent revenue from partnerships with global players like Boehringer Ingelheim highlights potential for milestone-driven upside, with Q3 results published May 13, 2026, drawing attention from NYSE American traders.

Conclusion

Palatin Technologies' Q3 fiscal 2026 results reflect a pivotal revenue milestone from collaborations, narrowing losses and strengthening cash reserves to $10.2 million as of March 31, 2026. With programs in dry eye and retinal disease advancing via partners like Boehringer Ingelheim, the company positions itself for potential clinical and financial catalysts. Investors monitoring NYSE American biotech names will watch upcoming milestones and pipeline progress.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.